AbbVie Gains 0.30% as Bimzelx Trial Challenges Skyrizi, Trading 70th in Volume Amid Mixed Analyst Outlooks

Market Snapshot

On March 11, 2026, AbbVie (ABBV) closed with a 0.30% increase, trading at $227.68 per share. The stock recorded a trading volume of 1.21 billion, ranking 70th in market activity for the day. While the modest gain suggests limited immediate market reaction to recent developments, the volume reflects moderate investor engagement. AbbVie’s share price remains within a 52-week range of $164.39 to $244.81, with a forward price-to-earnings ratio of 96.47 and a trailing earnings per share of $2.36. Analysts maintain a “Buy” consensus, with a 12-month average price target of $241.24, indicating long-term confidence despite short-term volatility.

Key Drivers

The recent head-to-head trial results between UCB’s Bimzelx and AbbVie’s Skyrizi have emerged as a critical factor influencing market sentiment. UCB announced that Bimzelx outperformed Skyrizi in the BE BOLD trial for psoriatic arthritis, achieving the primary endpoint of ACR50—a 50% improvement in American College of Rheumatology response criteria. The trial, which enrolled 553 patients, demonstrated Bimzelx’s statistical superiority over Skyrizi in alleviating joint and skin symptoms over 16 weeks. This outcome positions Bimzelx as a competitive alternative in a therapeutic area where IL-17 inhibitors have historically shown joint-targeting efficacy.

The trial’s methodology further amplified its significance. The ACR50 endpoint, combined with a 16-week evaluation period, structurally favors IL-17 inhibitors like Bimzelx over IL-23 blockers such as Skyrizi. Jefferies analyst Michael Leuchten noted that the trial design inherently benefits IL-17 biology in joint-dominant diseases, a dynamic that could reinforce UCB’s market position in the long term. Bimzelx’s well-tolerated safety profile—no new safety signals reported—adds to its appeal, potentially driving adoption among physicians and payers.

Despite these developments, analysts have tempered expectations regarding immediate market disruption. RBC Capital Markets’ Trung Huynh emphasized that the trial results, while positive for UCB, are unlikely to significantly alter Bimzelx’s sales trajectory in the near term. Skyrizi, a top-selling drug for AbbVie, maintains a robust presence in psoriatic arthritis and other inflammatory conditions, supported by its broader label and established market share. The competitive landscape remains fragmented, with IL-17 inhibitors like Novartis’ Cosentyx and Eli Lilly’s Taltz also vying for dominance.

AbbVie’s broader portfolio and ongoing innovation efforts provide a counterbalance to competitive pressures. Recent Phase 1 results for ABBV-295, a weight-loss asset, showed clinically meaningful, dose-dependent reductions in body weight, signaling potential in the obesity drug market. Analysts at RBC and Barclays have reiterated their positive outlooks, citing AbbVie’s diversified revenue streams, including immunology, oncology, and aesthetics, as well as its strong dividend yield and operating leverage. These factors underscore the company’s resilience amid therapeutic competition.

The stock’s modest 0.30% gain on March 11 reflects a balance between short-term uncertainty and long-term stability. While UCB’s trial results introduced volatility, AbbVie’s entrenched market position and pipeline advancements mitigate near-term risks. Investors appear to weigh the competitive dynamics of the biopharma sector against AbbVie’s structural advantages, including its $61.2 billion 2025 revenue and a 5.7% compound annual growth rate in its aseptic fill-finish manufacturing market. The coming months will likely hinge on data from upcoming trials, regulatory decisions, and the pace of market adoption for emerging therapies.